Cardiometabolic Health Congress

AUGUST 8, 2024

This blog post explores the development of such partnerships and their potential to transform healthcare outcomes. Engaging individuals as active participants in their care plans can significantly enhance outcomes and improve overall quality of life. Key contributions: Advanced cardiac imaging (e.g.,

Education 59

Education Cardiovascular Disease Diabetes Kidney Disease 59

Stroke Journal

JANUARY 30, 2025

Introduction:Chronic kidney disease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH.

Kidney Disease 40

Kidney Disease Hemorrhage Risk Factors Heart Disease 40

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

Stroke Journal

FEBRUARY 1, 2024

Introduction:Chronic kidney disease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH. In this study, we examined the relationship between ICH and CKD, as well as intracranial arterial calcification (IAC) as an intermediate biomarker.

Kidney Disease 40

Kidney Disease Hemorrhage Risk Factors Biomarkers 40

European Journal of Heart Failure

DECEMBER 1, 2023

A mixed model repeated measurements model (MMRM) was used to evaluate the effect of empagliflozin vs. placebo on the analysed biomarkers. On the other hand, PRO-C3, C1M, and C3M were not associated with worse HF severity or study outcomes.

Heart Failure 40

Heart Failure Biomarkers Kidney Disease Atrial Fibrillation 40

Open Heart

JULY 17, 2023

This study aimed to identify predictors of worse clinical outcome after deferral of non-emergency cardiovascular interventions. to 5.12; p=0.049), chronic kidney disease (HR 1.89; 95% CI 1.03 to 3.49; p=0.041) as well as severe valvular heart disease (HR 3.08; 95% CI 1.68 Arterial hypertension (HR 2.27; 95% CI 1.00

COVID-19 52

COVID-19 Outcomes Cardiovascular Interventions Risk Factors 52

European Journal of Heart Failure

AUGUST 24, 2023

CKD, chronic kidney disease; HFrEF, heart failure with reduced ejection fraction; Hb, hemoglobin; Htc, hematocrit; Fe - Intravenous iron; Sat, saturation; SGLT2i - sodium-glucose co-transporter 2 inhibitor. Secondary outcomes included changes in natriuretic peptides, kidney function and heart failure-associated outcomes.

Heart Failure 40

Heart Failure Kidney Disease Biomarkers Outcomes 40

Cardiometabolic Health Congress

SEPTEMBER 13, 2024

Measuring eGFR and albuminuria is recommended for assessing kidney disease in all hypertensive patients. Philip Moons (Belgium) presented the first results showing that patient-reported outcomes (PROs) vary significantly across different heart defects, and anatomical complexity is a poor predictor of PROs. Watch here!

Hypertension 59

Hypertension Cardiovascular Disease Bicuspid/Mitral Arrhythmia 59

Stroke Journal

JANUARY 30, 2025

Background and Purpose:Chronic kidney disease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025.

Atherosclerosis 40

Atherosclerosis Kidney Disease Blood Pressure Biomarkers 40

DAIC

JANUARY 23, 2024

5 Over my career as a cardiovascular surgeon, as well as an immunologist, I have witnessed how current treatments for ASCVD have led to considerable improvements in outcomes, yet many patients remain vulnerable to life-threatening cardiac events.1,6 34 The safety of colchicine, 0.5 μ/L on 0.6 N Engl J Med. 2019;381(26):2497-2505.

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Frontiers in Cardiovascular Medicine

APRIL 9, 2025

BackgroundChronic kidney disease (CKD) is a significant cardiovascular (CV) risk factor, with dialysis-dependent CKD (DD-CKD) patients facing high mortality rates. Citrate-based dialysates are known to reduce inflammatory biomarkers compared to acetate-based ones, potentially impacting lipid profiles and immune responses.

Cholesterol 52

Cholesterol Kidney Disease Risk Factors Biomarkers 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

With the holiday season approaching and fall in full swing, it’s the perfect time to reaffirm our commitment to delivering excellent care, improving patient outcomes, and making the most of every available resource. cardiometabolic health CME/CE conference: the 19th Annual CMHC. In the U.S.,

CME 103

CME Obesity Heart Failure Biomarkers 103

Open Heart

JANUARY 4, 2025

Background Acute kidney injury (AKI) in the context of acute decompensated heart failure (ADHF) encompasses a broad spectrum of phenotypes with associated disparate outcomes. AKI was defined using Kidney Disease Improving Global Outcomes (KDIGO) AKI criteria.

Heart Failure 40

Heart Failure Outcomes Kidney Disease Transplant 40

Dr. Smith's ECG Blog

FEBRUARY 26, 2025

Both reperfusion, as judged by the biomarker curve, and patency, as assessed by the angiogram, were correlated with the rapidity and depth of T wave inversion. The only other processes identified that caused this type of postinfarction T wave evolution were cardiopulmonary resuscitation, reinfarction, and very small infarcts.

Chest Pain 89

Chest Pain Pericarditis Myocardial Infarction Dementia 89